• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钆塞酸增强 MRI 诊断肝细胞癌的简化 LI-RADS

Simplified LI-RADS for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI.

机构信息

From the Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43 gil, Songpa-Gu, Seoul 05505, Korea.

出版信息

Radiology. 2022 Dec;305(3):614-622. doi: 10.1148/radiol.220659. Epub 2022 Aug 16.

DOI:10.1148/radiol.220659
PMID:35972362
Abstract

Background Although various modifications to the Liver Imaging Reporting and Data System (LI-RADS) at gadoxetic acid-enhanced MRI have been suggested, LI-RADS shows suboptimal sensitivity for hepatocellular carcinoma (HCC) and is perceived to be too complex. Purpose To evaluate clinical usefulness of a simplified LI-RADS for diagnosing HCCs of 30 mm or smaller at gadoxetic acid-enhanced MRI. Materials and Methods Patients who underwent gadoxetic acid-enhanced MRI examination and subsequent resection, transplantation, or biopsy for focal solid nodules of 30 mm or smaller between January 2019 and December 2020 at a single tertiary referral institution were retrospectively analyzed. Two strategies for simplified LI-RADS using one size criterion (≥10 mm) were evaluated (strategy A, using classifications for nodules of 10-19 mm for nodules both 10-19 mm and ≥20 mm; strategy B, using classifications for nodules ≥20 mm for nodules both 10-19 mm and ≥20 mm). Multivariable analysis was performed to determine significant ancillary features for HCC. Generalized estimating equations were used to compare diagnostic performance for LR-5 (definite HCC) between LI-RADS version 2018 and simplified LI-RADS. The time required for LI-RADS category assignment was compared between the two systems with use of a paired test. Results A total of 645 nodules from 510 patients (mean age ± SD, 60 years ± 10; 393 men) were evaluated. Compared with strategy A, strategy B had a higher sensitivity of 74% (347 of 470 nodules [95% CI: 70, 78]) vs 73% (342 of 470 nodules [95% CI: 69, 77]) ( = .02) with the same specificity of 96% (168 of 175 nodules [95% CI: 92, 98]) vs 96% (168 of 175 nodules [95% CI: 92, 98]) ( > .99). In strategy B, transitional phase hypointensity was an independent ancillary feature for HCC ( = .04) in LR-4 of at least 10 mm with arterial phase hyperenhancement and no other major features. In all 645 nodules, simplified LI-RADS with use of both strategy B and transitional phase hypointensity had a higher sensitivity of 82% (387 of 470 nodules [95% CI: 79, 86]) vs 73% (343 of 470 nodules [95% CI: 69, 77]) ( < .001) than LI-RADS version 2018, without lower specificity (94%, 165 of 175 nodules [95% CI: 90, 97] vs 96%, 168 of 175 nodules [95% CI: 92, 98], = .08). Compared with LI-RADS version 2018, simplified LI-RADS reduced the time for LI-RADS category assignment (44 seconds ± 23 vs 74 seconds ± 22, < .001). Conclusion A simplified Liver Imaging Reporting and Data System was found to be clinically useful for diagnosing hepatocellular carcinomas of 30 mm or smaller at gadoxetic acid-enhanced MRI. © RSNA, 2022

摘要

背景 虽然在钆塞酸增强 MRI 上对 Liver Imaging Reporting and Data System(LI-RADS)进行了各种修改,但 LI-RADS 对肝细胞癌(HCC)的敏感性不够,并且被认为过于复杂。目的 评估简化的 LI-RADS 在诊断钆塞酸增强 MRI 上直径为 30mm 或更小的 HCC 方面的临床应用价值。材料与方法 回顾性分析了 2019 年 1 月至 2020 年 12 月期间在一家三级转诊机构因直径为 30mm 或更小的局灶性实性结节而接受钆塞酸增强 MRI 检查并随后接受切除、移植或活检的患者。评估了两种简化 LI-RADS 的策略,使用一个大小标准(≥10mm)(策略 A,使用 10-19mm 和≥20mm 结节的分类用于 10-19mm 和≥20mm 的结节;策略 B,使用≥20mm 结节的分类用于 10-19mm 和≥20mm 的结节)。采用多变量分析确定 HCC 的显著辅助特征。采用广义估计方程比较 LI-RADS 版本 2018 与简化 LI-RADS 对 LR-5(明确 HCC)的诊断性能。使用配对 t 检验比较两种系统的 LI-RADS 类别分配时间。结果 共评估了 510 例患者(平均年龄±标准差,60 岁±10 岁;男性 393 例)的 645 个结节。与策略 A 相比,策略 B 的敏感性更高,为 74%(470 个结节中的 347 个[95%CI:70,78])与 73%(470 个结节中的 342 个[95%CI:69,77])(=.02),特异性相同,为 96%(175 个结节中的 168 个[95%CI:92,98])与 96%(175 个结节中的 168 个[95%CI:92,98])(>.99)。在策略 B 中,过渡相低信号是动脉期高增强且无其他主要特征的至少 10mm 的 LR-4 中 HCC 的独立辅助特征(=.04)。在所有 645 个结节中,使用策略 B 和过渡相低信号的简化 LI-RADS 的敏感性更高,为 82%(470 个结节中的 387 个[95%CI:79,86])与 73%(470 个结节中的 343 个[95%CI:69,77])(<.001),特异性无差异,为 94%(175 个结节中的 165 个[95%CI:90,97])与 96%(175 个结节中的 168 个[95%CI:92,98])(=.08)。与 LI-RADS 版本 2018 相比,简化 LI-RADS 减少了 LI-RADS 类别分配的时间(44 秒±23 秒与 74 秒±22 秒,<.001)。结论 简化的 Liver Imaging Reporting and Data System 在诊断钆塞酸增强 MRI 上直径为 30mm 或更小的 HCC 方面具有临床应用价值。

相似文献

1
Simplified LI-RADS for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI.钆塞酸增强 MRI 诊断肝细胞癌的简化 LI-RADS
Radiology. 2022 Dec;305(3):614-622. doi: 10.1148/radiol.220659. Epub 2022 Aug 16.
2
Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).在 1.5T 场强下使用肝脏影像报告和数据系统(LI-RADS v.2017)评估钆塞酸二钠与钆喷替酸葡甲胺对比用于肝细胞癌检测的效能。
Cancer Imaging. 2018 Dec 7;18(1):48. doi: 10.1186/s40644-018-0183-3.
3
Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates.LI-RADS v2018 对钆塞酸增强 MRI 检测肝移植候选者肝细胞癌的性能不佳。
Eur Radiol. 2024 Jan;34(1):465-474. doi: 10.1007/s00330-023-10014-6. Epub 2023 Aug 3.
4
LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI.LI-RADS v2018:如何在钆塞酸增强 MRI 上从中等恶性概率(LR-3)到可能 HCC(LR-4)的类别调整中适当使用辅助特征。
Eur Radiol. 2022 Jan;32(1):46-55. doi: 10.1007/s00330-021-08116-0. Epub 2021 Jun 16.
5
LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging.基于钆塞酸二钠增强磁共振成像的2018版肝脏影像报告和数据系统(LI-RADS)用于直径小于1.0厘米的肝细胞癌。
Eur Radiol. 2023 Aug;33(8):5792-5800. doi: 10.1007/s00330-023-09554-8. Epub 2023 Apr 5.
6
Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?改良版 LI-RADS 是否能提高 LI-RADS v2018 对钆塞酸增强 MRI 诊断 10-19mm 肝细胞癌的敏感性?
Abdom Radiol (NY). 2022 Feb;47(2):596-607. doi: 10.1007/s00261-021-03339-7. Epub 2021 Nov 13.
7
Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.2018KLCA-NCC 肝细胞癌诊治指南在慢性乙型肝炎或肝硬化患者钆塞酸增强 MRI 中的诊断性能:与 LI-RADS 2018 版的比较
Korean J Radiol. 2021 Jul;22(7):1066-1076. doi: 10.3348/kjr.2020.0846. Epub 2021 Mar 9.
8
LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.LI-RADS v2014 肝细胞癌分类:钆喷酸葡胺增强 MRI 与钆塞酸二钠增强 MRI 的个体内比较。
Eur Radiol. 2019 Jan;29(1):401-410. doi: 10.1007/s00330-018-5559-z. Epub 2018 Jun 19.
9
LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.LI-RADS 版本 2017 与版本 2018:钆塞酸二钠增强 MRI 诊断肝细胞癌。
Radiology. 2019 Sep;292(3):655-663. doi: 10.1148/radiol.2019182867. Epub 2019 Jul 16.
10
Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid-enhanced MRI.钆塞酸增强 MRI 应用肝脏影像报告和数据系统 2018 年辅助特征升级至 LR-5。
Eur Radiol. 2021 Feb;31(2):855-863. doi: 10.1007/s00330-020-07146-4. Epub 2020 Aug 18.

引用本文的文献

1
Interactive Explainable Deep Learning Model for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI: A Retrospective, Multicenter, Diagnostic Study.用于钆塞酸二钠增强MRI肝细胞癌诊断的交互式可解释深度学习模型:一项回顾性、多中心诊断研究
Radiol Imaging Cancer. 2025 May;7(3):e240332. doi: 10.1148/rycan.240332.
2
Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients.采用六氟化硫或全氟丁烷的CT/MRI肝脏影像报告和数据系统(LI-RADS)联合二线对比增强超声检查用于诊断高危患者肝细胞癌
Korean J Radiol. 2025 Apr;26(4):346-359. doi: 10.3348/kjr.2024.0980. Epub 2025 Feb 20.
3
Simplified liver imaging reporting and data system for the diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging.
用于钆塞酸二钠增强磁共振成像诊断肝细胞癌的简化肝脏影像报告和数据系统
World J Gastrointest Oncol. 2024 Jun 15;16(6):2439-2448. doi: 10.4251/wjgo.v16.i6.2439.
4
Prognostic Factors for Patients with Proliferative Hepatocellular Carcinoma After Liver Resection.肝切除术后增殖性肝细胞癌患者的预后因素
J Hepatocell Carcinoma. 2023 Nov 20;10:2059-2071. doi: 10.2147/JHC.S440636. eCollection 2023.
5
Local anaesthesia vs. general anaesthesia for percutaneous microwave ablation in hepatocellular carcinoma: efficacy, safety, and cost analysis.局部麻醉与全身麻醉用于肝细胞癌经皮微波消融的疗效、安全性及成本分析
Front Oncol. 2023 Sep 12;13:1186133. doi: 10.3389/fonc.2023.1186133. eCollection 2023.
6
[CT/MRI Liver Imaging Reporting and Data System (LI-RADS): Standardization, Evidence, and Future Direction].[CT/MRI肝脏影像报告和数据系统(LI-RADS):标准化、证据及未来方向]
J Korean Soc Radiol. 2023 Jan;84(1):15-33. doi: 10.3348/jksr.2022.0144. Epub 2023 Jan 30.